首页 | 本学科首页   官方微博 | 高级检索  
     

人乳腺癌细胞原代培养体外药敏试验及Her-2、TopoⅡ的表达
引用本文:李艳兵,严斌,石岚,田园,江斌. 人乳腺癌细胞原代培养体外药敏试验及Her-2、TopoⅡ的表达[J]. 郧阳医学院学报, 2009, 28(5)
作者姓名:李艳兵  严斌  石岚  田园  江斌
作者单位:李艳兵,严斌,江斌(郧阳医学院附属太和医院普外科,湖北,十堰,442000);石岚,田园(武汉市协和医院乳甲外科,湖北,武汉430022) 
摘    要:目的:研究4种化疗药物对原代培养人乳腺癌细胞的敏感性,结合Her-2、TopoⅡ免疫组化表达结果,分析药敏结果与表达的相关性及临床意义。方法:利用CCK8法检测4种化疗药物对乳腺癌原代细胞生长的影响,免疫组织化学方法检测细胞中Her-2、TopoⅡ的表达情况。结果:⑴4种化疗药物在不同浓度下对乳腺癌细胞的抑制率排序为:紫杉醇>长春瑞滨>阿霉素>卡铂,紫杉醇剂量与疗效之间有量效关系,而阿霉素、长春瑞滨和卡铂则不存在量效关系;⑵Her-2、TopoⅡ阳性表达率分别为25.4%和53.9%;⑶紫杉醇、长春瑞滨、阿霉素对Her-2阳性、TopoⅡ阳性细胞的生长有显著的抑制作用(P<0.05),而卡铂则无显著性抑制作用。结论:原代培养肿瘤细胞的体外药敏试验对临床肿瘤的化疗有很强的指导作用,Her-2、TopoⅡ可作为判断预后很好参考指标。

关 键 词:乳腺癌  原代培养  Her-2  TopoⅡ

Chemosensitivity of Primary Cultured Human Breast Cancer Cells in Vitro and Its Expression of Her-2 and TopoⅡ
Abstract:Objective To investigate the chemosensitivity to four kinds of chemotherapeutic drugs in primary cultured human breast cancer cells,and to analyze the relationship between the sensitivity results and the expressions of Her-2,TopoⅡ and its clinical siginificance based on the immunohistochemical results.Methods The effects of four kinds of chemotherapeutic drugs on primary cultured human breast cancer cells were detected with CCK8,the expressions of Her-2,TopoⅡ were determined with immunohistochemical method.Results ⑴ The ranking of inhibitory effect of 4 drugs at different concentration was as follows:paclitaxel>vinorelbine>adriamycin>carboplatin,the inhibitory effct of paclitaxel was dose-dependent,but there was no dose-effect relationship in vinorelbine,adriamycin and carboplatin;⑵the positive rates of Her-2,TopoⅡ were 25.4% and 53.9%,respectively;⑶the growth of Her-2,TopoⅡ positive cells were significantly inhibited with paclitaxel,doxorubicin,vinorelbine(P <0.05),while the inhibitory effect was not found in carboplatin.Conclusion The chemosensitivity study of primary cultured cancer cells may play important roles in selecting regimen of chemotherapy,Her-2 and TopoⅡ could be sensitive indicators for judging prognosis.
Keywords:Her-2  Topo
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号